Ratings DukSan Neolux Co.,Ltd

Equities

A213420

KR7213420003

End-of-day quote Korea S.E. 18:00:00 2024-04-29 EDT 5-day change 1st Jan Change
38,400 KRW +0.52% Intraday chart for DukSan Neolux Co.,Ltd +6.22% -13.71%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 53% by 2026.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.

Weaknesses

  • With an enterprise value anticipated at 4530.09 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

Ratings chart - Surperformance

Sector: Specialty Chemicals

1st Jan change Capi. Investor Rating ESG Refinitiv
-13.71% 682M -
+14.02% 63.38B
A-
-3.80% 46.51B
A-
+13.26% 39.91B
B+
+19.57% 25.57B
A-
+8.22% 18.95B
C+
-1.13% 17.58B
B+
-21.03% 16.1B
A-
+1.06% 14.98B
B+
-16.73% 14.78B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. A213420 Stock
  4. Ratings DukSan Neolux Co.,Ltd